Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789739 | 1.00 | APP (0.61) | APPCYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL10810527 | 0.95 | CYP1A1 (0.57) | APPCYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL10810517 | 0.95 | CYP1A1 (0.57) | APPCYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL6222426 | 0.86 | APP (0.58) | APPCYP1A1CYP1B1ATMESR1 | |
| SCHEMBL22882052 | 0.86 | CYP1A2 (0.54) | CYP1A1CYP1B1MAOBCYP1A2PPARA | |
| SCHEMBL6222428 | 0.86 | APP (0.58) | APPCYP1A1CYP1B1ATMESR1 | |
| SCHEMBL1689725 | 0.85 | CA12 (0.67) | CYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL1689727 | 0.85 | CA12 (0.67) | CYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL22881930 | 0.85 | HDAC3 (0.50) | CYP1A1CYP1B1MAOBCYP1A2PPARA | |
| SCHEMBL22816513 | 0.85 | APP (0.60) | APPATMLMNASMN1; SMN2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784295-B2 | CARRIED OUT IN THE PRESENCE OF AN INORGANIC BASE OR ORGANIC NITROGEN BASE AND A PALLADIUM COMPLEX CATALYST CONTAINING SECONDARY MONOPHOSPHINES WITH ALIPHATIC, BRANCHED OR CYCLIC SUBSTITUENTS AS LIGANDS | SOLVIAS AG (CH) | 2004-08-31 | — | — | US | disclosed |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | INDOLESE ADRIANO (CH) | 2003-09-25 | — | — | US | disclosed |
| EP-1132361-B1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-6548684-B2 | Using monophosphine palladium complex catalyst | SOLVIAS AG (SE) | 2003-04-15 | — | — | US | disclosed |
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2001-11-01 | — | — | US | disclosed |
| EP-1132361-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | Solvias AG (CH) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | APP 3926/4885CYP1A1 456/4885CYP1B1 455/4885 |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | APP 3926/4885CYP1A1 456/4885CYP1B1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.